Abstract
Recurrent vulvovaginal candidiasis (RVVC) is by no means uncommon and is a source of considerable physical discomfort in addition to serving as a major therapeutic challenge. The syndrome is multifactorial in aetiology and hence management strategies must recognise the complex aetiological pathways. Many women receiving the misplaced diagnosis of RVVC have a variety of other infectious and non-infectious entities presenting with identical symptoms. Hence the first step in management is confirming the diagnosis of RVVC including microbial confirmation and species identification. Efforts should be made to identify and correct a causal mechanism. Maintenance suppressive azole anti-fungal regimens are highly effective in controlling symptoms, although cure is less common. Further advances in achieving higher cure rates await the availabilityof non-azole fungicidal agents.
Similar content being viewed by others
References
Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1985; 152: 924–35
Foxman B, Marsh JV, Gillespie B, et al. Frequency and response to vaginal symptoms among white and black women: results of a random digital dialing survey. J Womens Health 1998; 7: 1167–74
Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178: 203–11
Sobel JD, Kapernik P, Zervos M, et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001; 185: 363–9
Lynch ME, Sobel JD. Comparative in vitro activity of antimycotic against pathogenic vaginal yeast isolates. J Med Vet Mycol 1994; 32: 267–74
Vazquez JA, Sobel JD, Demitriou R, et al. Karotyping of C. albicans obtained longitudinally in women with recurrent vulvovaginal candidiasis. J Infect Dis 1994; 170: 1566–9
Sobel JD. Pathogenesis of recurrent vulvovaginal candidiasis. Curr Infect Dis Rep 2002; 4: 514–9
Fidel Jr PL, Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 1996; 9: 335–48
Sobel JD. Recurrent vulvovaginal candidiasis: a prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med 1986; 315: 1455–8
Sobel JD. Fluconazole maintenance therapy in recurrent vulvovaginal candidiasis. Int J Gynecol Obstet 1992; 37: 17–34
Houang ET, Chappatte O, Byrne D, et al. Fluconazole levels in plasma and vaginal secretions of patients with the 150mg single does and rate of eradication of infections in vaginal candidiasis. Antimicrob Agents Chemother 1990; 34: 909–13
Ritter W. Pharmacokinetics fundamentals of vaginal treatment with clotrimazole. Am J Obstet Gynecol 1985; 152: 945–7
Davidson F, Mould RF. Recurrent genital candidosis in women and the effect of intermittent prophylactic treatment. Br J Vener Dis 1978; 54: 176–83
Stein GE, Mummau ML, Schooky SL. Prevention of recurrence vaginal candidiasis with weekly terconazole cream. Ann Pharmacother 1996; 30: 1080–3
Tooley PJ. Patient and doctor preference in the treatment of vaginal candidiasis. Practitioner 1985; 229: 655–60
Fong IW. The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourin Med 1992; 68: 174–6
Spinillo A, Carratta L, Pizzoli G, et al. Recurrent vaginal candidiasis: results of a cohort study of sexual transmission and intestinal reservoir. J Reprod Med 1992; 37: 343–7
Dennerstein GJ. Depo-Provera in the treatment of recurrent vulvovaginal candidiasis. J Reprod Med 1986; 31: 801–3
Hilton E, Isenberg HD, Alperstein P, et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992; 116: 353–7
Rosedale N, Braue K. Hyposensitization in the management of recurring vaginal candidiasis. Ann Allergy 1979; 43: 250–3
Rigg D, Miller MM, Metzger WJ. Recurrent allergic vulvovaginitis treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol 1990; 162: 332–9
Sobel JD, Chaim W. Therapy of T. glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis 1997; 24: 649–52
Sobel JD, Ohmit SE, Schuman P, et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from HIV-seropositive and at-risk seronegative women. J Infect Dis 2001; 182: 286–93
Schuman P, Capps L, Peng G, et al. Prevention of mucosal candidiasis in women infected with the human immunodeficiency virus (HIV): a randomized, double-blind study comparing weekly fluconazole prophylaxis with placebo. Ann Intern Med 1997; 126: 689–96
Acknowledgements
No sources of funding were used to assist in the preparation of this manuscript. The author has no conflicts of interest that are directly relevant to the content of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sobel, J.D. Management of Patients with Recurrent Vulvovaginal Candidiasis. Drugs 63, 1059–1066 (2003). https://doi.org/10.2165/00003495-200363110-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200363110-00002